Schedule a Call


Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

ProMIS Neurosciences, Inc.

Location: Toronto, ON

Sector: Life Sciences


Add to Shortlist
Express Interest

Our mission is to discover and develop precision medicine therapeutics for disease modifying treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

As its primary objective, the Company will focus on the discovery and development of specific therapeutics and companion diagnostics directed against the several strains of misfolded (prion-like) Amyloid beta (Aβ) in Alzheimer’s.

Business Documents

MG cp Summary
  • Alzheimer’s Disease (AD) is largest chronic unmet medical need – Over 5 million patients in North America with full blown Alzheimer’s disease, and a further 10 million in earlier stages of AD; Current medical costs in USA estimated at hundreds of billions of dollars, and expected to triple over next 15 years.
  • ProMIS has multiple, product candidates identified for AD – Precisely targeted against prion strains of Amyloid beta (Aβ), the root cause of Alzheimer’s.
  • Unique science team and experience – Deep understanding of prion forms of proteins, with use of proprietary algorithms for identifying and patenting targets and therapeutics for AD and other neurodegenerative diseases.
  • Breadth of granted and emerging patent estate
    • in ALS, robust patent estate granted worldwide for SOD1 related targets & antibody therapeutics;
    • in AD, provisional patents for misfolded Aβ targets submitted (n=4) or planned (n=2) for submission;
    • proprietary algorithms, patents granted worldwide for ProMISTM, submitted for Collective Coordinates technology.

As its primary objective, the Company focuses on the discovery and development of precision therapeutics and companion diagnostics directed against prion strains of Amyloid beta (Aβ), the root cause of Alzheimer’s.

In Alzheimer’s, ProMIS has identified six distinct epitope targets uniquely associated with the prion forms of Aβ, created murine antibodies against these targets, and on screening has identified multiple product candidates for each of these targets, as announced on June 2, 2016.

We are currently conducting validation studies with cadaveric brain tissue from Alzheimer’s patients in order to select among these product candidates the best to take forward for clinical development. In all cases, our epitope identification allows us to create companion diagnostics, enabling a precision medicine approach to clinical trials and treatment selection for patients.

In ALS, we have three murine antibodies that have been validated as selective for strains of misfolded SOD1. Misfolded, prion-like SOD1 is known to play a key role in the progression of ALS. We are actively seeking a partner, or collaborative partnership for this portfolio, which is covered by an extensive IP estate.

Elliot P Goldstein, MD, President & CEO

Elliot Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals in 1980 (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham for 4 yrs. (now GSK), CEO of British Biotech (Oxford, UK) for 4 yrs., Chief Operating Officer and Chief Medical Officer of Maxygen for 7 yrs., and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies

Eugene Williams, MBA, Executive Chairman

Eugene Williams has been a successful biotech and life sciences senior executive, entrepreneur, and innovator for more than 30 years.   His experience spans the spectrum from new start-ups to senior roles in one of the largest and most successful global biotech companies.   His functional area experience includes early and late stage drug development, deal making, biotech commercialization, and healthcare services.   After starting his career in strategy consulting at Bain and company and a spinoff of Bain, he joined Genzyme in the late 1990’s.   He managed the Genzyme therapeutics development portfolio when Genzyme expanded its Orphan Disease business from a single product to multiple products.   His responsibilities included managing the processes by which Genzyme evaluated in-licensing opportunities. As an entrepreneur, he was a founder and director of Adheris, Inc. which became the leading service company addressing patient adherence, and which sold to InVentiv in a deal generating greater than 15x cash on cash returns for investors.   He founded service companies supporting drug development in India and China, and was a founder of DART (now Akashi) an innovative biotech funded by patient foundations focused on Duchenne Muscular Dystrophy.

Neil R. Cashman, MD, Chief Science Officer

Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

Steven Plotkin, PhD, Chief Physics Officer

Prof. Steven Plotkin is a theoretical and computational biophysicist whose research focuses on protein folding and misfolding in neurodegenerative disease, protein evolution and cellular differentiation, and the molecular mechanisms of cancer. He has been a professor at UBC in the Department of Physics and Astronomy since 2001, where he was appointed as the Canada Research Chair in Theoretical Molecular Biophysics. He was an Alfred P. Sloan Research Fellow in 2005-2006, a Killam Faculty Research Fellow in 2010, and is now an associate member of the Genome Sciences and Technology Program, the Bioinformatics Program, and the Institute for Applied Mathematics at the University of British Columbia. Several of his publications have received the Faculty of 1000 designation, placing them in the top 2% of published articles in biology and medicine.
Plotkin is recognized internationally for his fundamental contributions to the energy landscape theory of protein folding, and presents his research findings in protein misfolding and neurodegeneration, and protein geometry and disorder as an invited speaker at several annual conferences and symposia. His research is currently supported by grants from CIHR, NSERC, APRI, ALS-Canada, and Compute Canada.